跳至主要内容
临床试验/NCT00997997
NCT00997997已完成不适用

ARTOS - Avelox® in Routine Treatment of Complicated Skin and Skin Structure Infections

Bayer0 个研究点目标入组 6,127 人开始时间: 2005年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
6,127
主要终点
Efficacy: course of severity of infection, course of clinical signs and symptoms, duration until improvement, duration until recovery, duration until wound closure, overall assessment of efficacy by the physician, reuse of Avelox

研究概览

简要总结

This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions. Specifically investigated are the improvement of clinical symptoms and the duration until infection improvement and cure.Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) treated with Avelox can be documented. The observation period for each subject covers the treatment period with Avelox. For each patient, the physician documents data at an initial visit and one or two follow-up visit(s) in line with routine practice.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
10 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) and for whom the decision was made by the attending physician to start treatment with Avelox before inclusion into and independent of the study.

排除标准

  • Exclusion criteria are those specified in the local product information.

研究组 & 干预措施

Group 1

干预措施: Moxifloxacin (Avelox, BAY12-8039) (Drug)

结局指标

主要结局

Efficacy: course of severity of infection, course of clinical signs and symptoms, duration until improvement, duration until recovery, duration until wound closure, overall assessment of efficacy by the physician, reuse of Avelox

时间窗: last documented follow-up visit, according to the respective praxis routine

次要结局

  • Adverse events collection(during entire study course, according to the respective praxis routine)
  • Overall assessment of tolerability by the physician(last documented follow-up visit, according to the respective praxis routine)

研究者

发起方
Bayer
申办方类型
Industry

相似试验